Tag Archives: systolic heart failure

Introduction Heart failure with reduced ejection fraction (HFrEF) is a significant healthcare burden internationally, with an age-standardised prevalence of approximately 3.8% in women and 4.6% in men, and an estimated five-year mortality rate of 43%.1,2 Hospitalisations for heart failure exacerbations represent a major financial challenge to health services, and such patients have a higher risk of readmission and mortality.3 Previously, the DAPA-HF (Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction) trial demonstrated that dapagliflozin significantly reduces the risk of worsening heart failure and cardiovascular deat

Introduction Systolic heart failure (SHF) in patients with severe aortic stenosis (AS) carries a worse prognosis, and aortic valve replacement improves ventricular systolic function and survival.1,2 Therefore, SHF is an indication for aortic valve replacement in severe AS.2 Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are associated with comparable survival and ventricular systolic function recovery in this group of patients.3 TAVR, however, is the recommended approach for patients with intermediate to prohibitive surgical risk; and SHF patients are often considered a high-risk group. As a re